Historically, adverse effects of medicines have been identified through spontaneous adverse reaction reporting followed by ‘ad hoc’ studies designed to quantify risk.  Widespread access to large linked routinely collected databases made this process more efficient, but it often takes years for separate research groups to collectively address an important safety question. In response, several collaborations have formed internationally that enable simultaneous analyses of data bases in multiple jurisdictions. The Canadian Network for Observational Drug Effect Studies was established in 2011 and since then 120 researchers in 8 provinces have performed over 120 analyses of large population data-bases from 10 jurisdictions. This work has confirmed specific risks or demonstrated relative safety of several major drug classes, including anti-microbials, anti-psychotics, incretin-based drugs, opioids, statins, retinoids, acid pump inhibitors, anticoagulants, biologics and anti-emetics. Distributed analysis ensures that a common analytical protocol is applied to multiple data-bases, comprising a possible total population of 100 million or more. A Methods team ensures consistency of work across sites and monitors factors that might introduce bias into treatment effect estimates.  A COI management policy limits the roles of individuals who have any links to manufacturers and a knowledge translation group.

Speaker Bio

David HenryDavid Henry , (Bond University)

Is a Professor at the Institute for Evidence-Based Healthcare at Bond University. He also holds conjoint positions at the University of Newcastle, University of Melbourne and an Emeritus Chair at the University of Toronto. He also worked as an internal medicine specialist for many years after completing training in clinical pharmacology and gastroenterology. His research has been mainly in the fields of pharmacoepidemiology and WHO medicines policies in both high- and low-income countries. He was active in the development of drug subsidization programs in Australia and South Africa.

About Seminar Series

The School of Pharmacy Seminar Series involves regular formal presentations of high-quality scholarly work with broad appeal.

The wider School community is invited to attend, including academic and professional staff, special guests, visitors, as well as HDR, postgraduate, masters and honours students.

Seminars are held on Fridays from 12pm–1pm in room 5034 in the Pharmacy Australia Centre of Excellence, 20 Cornwall St Woolloongabba (next to TRI and the PA Hospital).

Confirmed 2021 seminars

Date Presenter
12-1pm, Friday 19 March
(PACE R5034 and Zoom)
Professor Paul Clarke, Director Diamantina Institute        
12-1pm, Friday 16 April
(Zoom only)
Associate Professor Francine Marques, Monash University     
12-1pm, Friday 23 April
(Zoom only)
Associate Professor Ben Colagiuri, Sydney University 
12-1pm, Friday 7 May
(Zoom only)
Dr Laurence Cheung, Curtin University
12-1pm, Friday 30 July
(location TBC)
Dr Gary Chan, UQ CYSUR
12-1pm, Friday 13 August
(Zoom only)
Professor Sanjay Garg, University of South Australia
12-1pm, Friday 3 September
(PACE R5034 and Zoom)
Associate Professor Michael Barras, UQ Pharmacy
12-1pm 10 September
(Online via Zoom)

Professor Josephine Forbes, Mater Research


12-1pm, Friday 17 September
(PACE R5034 and Zoom)

Professor Nigel McMillan, Program Director: Infectious Diseases and Immunology, Menzies Health Institute QLD, Griffith University

12-1pm, Friday 24 September
(Location TBC)
Denuja Karunakaran, IMB Fellow, Institute for Molecular Bioscience (IMB), UQ


Pharmacy Australia Centre of Excellence, 20 Cornwall St, Woolloongabba